Form 4: ResMed CEO Michael Farrell Executes Stock Options and Sells Shares Under 10b5-1 Plan

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 7, 2024, Michael J. Farrell, the CEO of ResMed Inc., executed stock options to acquire 1,176 shares and 13,507 shares of ResMed Common Stock at an exercise price of $84.98 per share.
• Following the exercise of these options, Farrell sold 14,683 shares of ResMed Common Stock at a weighted average price of $216.4963, with individual sales prices ranging from $215.71 to $217.08.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on January 31, 2024.
• After these transactions, Farrell directly owns 440,752 shares of ResMed Common Stock.
• Farrell also indirectly owns shares through the Lisette and Michael Farrell Foundation (0 shares), the Lisette and Michael Farrell Family Trust (4,090 shares), and the Lisette & Michael Farrell Family Foundation (0 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-arranged plan, with no indication of significant positive or negative implications for the company.

Positives

• The CEO's transactions are being conducted under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• There are no specific risks mentioned in this document.

Industry Context

This type of filing is common for executives of publicly traded companies and provides transparency into their trading activities. It is important for investors to understand the context of these transactions, especially when they are conducted under pre-arranged trading plans.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice in publicly traded companies, particularly in the healthcare and technology sectors.
• Companies like Medtronic, Stryker, and Philips also see similar filings from their executives related to stock transactions.
• The use of Rule 10b5-1 plans is a standard method for executives to manage their stock holdings while avoiding potential insider trading accusations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the CEO's sale of shares, but the pre-planned nature of the transactions mitigates potential concerns.

Key Dates